Combined study on clastogenic, aneugenic and apoptotic properties of doxorubicin in human cells in vitro

Table 2 Mitotic figure distribution and the effect on the M.I. in C₂C₁₂ cells treated with doxorubicin

Chemical compound (μg ml⁻¹)	Total mitotic cells	Prophases (%) Mean ± SE	Metaphases (%) Mean ± SE	Ana-telophases (%) Mean ± SE	Total abnormal mitotic cells (%) Mean ± SE	Total abnormal metaphases (%) Mean ± SE	Mitotic Index (%) Mean ± SE
0	1436	24 1.69 ± 0.25	474 32.88 ± 2.03	938 65.44 ± 1.78	152 10.51 ± 1.12	149 10.51 ± 1.07	5.86 5.87 ± 0.57
DOX 0.05	658	5 0.79^* ± 0.79	159 24.15^* ± 0.49	494 75.07^* ± 0.31	477 72.69^* ± 5.54	112 17.04^* ± 0.32	1.34 1.34^* ± 0.03
DEM 0.005	650	9 1.38^* ± 0.06	425 64.85^* ± 7.57	216 33.77^* ± 7.62	409 62.49^* ± 6.20	385 58.78^* ± 6.46	2.14 2.14^* ± 0.07

DOX doxorubicin, DEM demecolcine was used as positive control, M.I. Mitotic Index, SE standard error
* p ≤ 0.0001 in comparison with control (G-test)

ISSN: 2241-5793